Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

183.91
+1.590.87%
Volume:373.71K
Turnover:68.57M
Market Cap:11.32B
PE:-31.49
High:184.76
Open:181.77
Low:180.68
Close:182.32
52wk High:198.00
52wk Low:95.49
Shares:61.56M
Float Shares:58.65M
Volume Ratio:0.93
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8403
EPS(LYR):-5.8403
ROE:-8.47%
ROA:5.22%
PB:2.62
PE(LYR):-31.49

Loading ...

BUZZ-Jazz Pharma jumps after cancer drug meets main goal in late-stage study

Reuters
·
Nov 17, 2025

BRIEF-Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Reuters
·
Nov 17, 2025

Jazz Pharmaceuticals Plc: Plans to Submit a Supplemental Bla for This Indication in First Half of 2026

THOMSON REUTERS
·
Nov 17, 2025

Positive Herizon-Gea-01 Phase 3 Results Support Ziihera® (Zanidatamab-Hrii) as Her2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line Her2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Nov 17, 2025

Zymeworks Reports Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Reuters
·
Nov 17, 2025

A Look at Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Earnings, Guidance Boost, and Modeyso Approval

Simply Wall St.
·
Nov 13, 2025

Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer

Reuters
·
Nov 12, 2025

RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Nov 12, 2025

BRIEF-Jazz Pharmaceuticals Showcases New Clinical And Translational Data For Modeyso

Reuters
·
Nov 11, 2025

Jazz Pharmaceuticals Unveils New Clinical Data for Modeyso in H3 K27M-Mutant Glioma at SNO 2025

Reuters
·
Nov 11, 2025

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (Dordaviprone) in H3 K27m-Mutant Diffuse Midline Glioma at Sno 2025

THOMSON REUTERS
·
Nov 11, 2025

Is Jazz Pharmaceuticals a Bargain After Product Launches and a 5% Weekly Dip?

Simply Wall St.
·
Nov 10, 2025

Stock Track | Jazz Pharmaceuticals Soars 5.01% on Strong Q3 Earnings and Raised Guidance

Stock Track
·
Nov 06, 2025

Jazz Pharmaceuticals Plc : Morgan Stanley Raises Target Price to $185 From $183

THOMSON REUTERS
·
Nov 06, 2025

Morgan Stanley Lifts Price Target on Jazz Pharmaceuticals to $185 From $183, Keeps Overweight Rating

MT Newswires Live
·
Nov 06, 2025

GUIDANCE: (JAZZ) Jazz Pharmaceuticals Expects Full Year 2025 Revenue Range $4.18 Billion - $4.28 Billion, vs. FactSet Est of $4.22 Billion

MT Newswires Live
·
Nov 06, 2025

BRIEF-Jazz Pharmaceuticals Q3 Adjusted EPS USD 8.13 Vs. IBES Estimate USD 5.97

Reuters
·
Nov 06, 2025

A Fresh Look at Jazz Pharmaceuticals (JAZZ) Valuation Following Landmark Settlement With Avadel

Simply Wall St.
·
Nov 04, 2025

Are Jazz Pharmaceuticals Shares Still Attractive After a 25% Climb and New Pipeline Developments?

Simply Wall St.
·
Nov 02, 2025

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

THOMSON REUTERS
·
Nov 02, 2025